Related Experiment Video
Updated: Apr 29, 2026
07:42
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
7.1K
Thyroid dysfunctions induced by tyrosine kinase inhibitors
Poupak Fallahi1, Silvia M Ferrari, Roberto Vita
1University of Pisa, Department of Clinical and Experimental Medicine , Via Savi 10, 56126, Pisa , Italy.
Expert Opinion on Drug Safety
|May 14, 2014
Summary
Tyrosine kinase inhibitors (TKIs) can cause thyroid dysfunction. Routine monitoring and careful consideration of thyroid hormone therapy are essential for patients receiving TKIs.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) represent a novel class of anticancer agents.
- While less toxic than traditional chemotherapy, TKIs are associated with significant side effects, including fatigue, hypertension, and thyroid dysfunction.
Purpose of the Study:
- To comprehensively review TKI-induced thyroid dysfunctions.
- To evaluate the mechanisms, clinical impact, and treatment controversies of TKI-induced thyroid dysfunction.
Main Methods:
- Systematic review of literature on TKI-induced thyroid dysfunction.
- Assessment of specific TKIs: sunitinib, sorafenib, pazopanib, imatinib, dasatinib, nilotinib, vandetanib, axitinib, motesanib, and tivozanib.
- Evaluation of potential mechanisms, clinical impact, and thyroid hormone (TH) therapy controversies.
Main Results:
- Thyroid dysfunction is a recognized adverse effect of various TKIs.
- The review details specific TKIs linked to thyroid dysfunction.
- Mechanisms, clinical significance, and treatment debates are explored.
Conclusions:
- Routine thyroid function monitoring is crucial for patients on TKIs.
- The benefits of thyroid dysfunction and the risks of treatment require further controlled studies.
- Prospective clinical evaluation is needed to determine optimal thyroid hormone replacement dosing and timing.
Keywords:
axitinibdasatinibhyperthyroidismhypothyroidismimatinibmotesanibnilotinibpazopanibsorafenibsunitinibthyroid cancerthyroid dysfunctionstivozanibtyrosine kinase inhibitorsvandetanibMore Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
661
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
17.5K
Related Concept Videos
01:27Hyperthyroidism II: Pathophysiology
27
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
27
01:25Hyperthyroidism I: Introduction
30
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
01:23Hypothyroidism II: Pathophysiology
26
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
26
01:24Graves Disease II: Pathophysiology
26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
01:20Synthesis and Regulation of Thyroid Hormones
7.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K
01:26Receptor Tyrosine Kinases
15.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K